Keros Therapeutics, Inc. (KROS) research

Keros Therapeutics, Inc.
ShareXLinkedInReddit
Sector
Biotechnology
Last price
$11.48
As of

Keros Therapeutics, Inc. (KROS): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-08.

As of . Source: SEC EDGAR filings for KROS. Method and limitations.

SHARE THIS CARD

Share the KROS intelligence card

A branded snapshot of KROS: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion KROS intelligence card preview
Post to X
LIVE TERMINAL

See KROS live in the terminal

Track KROS's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live KROS terminal, free

Active signals for KROS

FREE, NO ACCOUNT

Every signal on KROS, as it fires

You are seeing 5 of 21 signals recorded on KROS since 2026-06-09.

The five above all landed on 2026-09-06. The other 16 were recorded on 4 other days. 16 of the 21 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in KROS (2026Q2)

Manager / securityMarket value% portfolioQoQ
CITADEL ADVISORS LLCCUSIP 492327101 · 2026Q2$4.2M0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 492327101 · 2026Q2$3.8M0.01%,
D. E. Shaw & Co., Inc.CUSIP 492327101 · 2026Q2$2.9M0.00%,
TWO SIGMA INVESTMENTS, LPCUSIP 492327101 · 2026Q2$2.6M0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP 492327101 · 2026Q2$2M0.00%,
Point72 Asset Management, L.P.CUSIP 492327101 · 2026Q2$111K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, KROS

KROS against its peers

KROS's operating margin of 27.7% ranks in the 91st percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.

MetricKROSPeer medianPercentilen
Revenue FY244M USD21.0M USD9715
Operating margin27.7%-429.5%9115
Net margin35.7%-229.6%7815
Return on equity28.7%-33.3%8319
P / E5.0xn/an/a3

Peers (24): PLX, NGEN, IVVD, AVXL, YDES, ADAG, ALEC, ELDN, CGEN, WHWK, IPHA, CHRS, PEPG, ALXO, NAGE, CUE, NKTX, RNAC, TARA, SRZN, FHTX, ORMP, MSLE, CNTN. Left out: VRXA (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (KROS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more KROS signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to KROSand get the insider, 13F, options, and confluence read in one view.

Open the live KROS terminal, free